{
    "organizations": [],
    "uuid": "24bd18f7a9c0fb14b1d57071bf200586ffc7abb9",
    "author": "",
    "url": "https://www.reuters.com/article/brief-european-commission-approves-adcet/brief-european-commission-approves-adcetris-for-cd30-positive-cutaneous-t-cell-lymphoma-idUSFWN1PH0NU",
    "ord_in_thread": 0,
    "title": "BRIEF-European Commission Approves Adcetris For CD30-Positive Cutaneous T-Cell Lymphoma",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 22, 2018 / 1:30 PM / Updated 8 minutes ago BRIEF-European Commission Approves Adcetris For CD30-Positive Cutaneous T-Cell Lymphoma Reuters Staff 1 Min Read \nJan 22 (Reuters) - Takeda Pharmaceutical Co Ltd: \n* EUROPEAN COMMISSION APPROVES ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER ONE PRIOR SYSTEMIC THERAPY– PROVIDING AN INNOVATIVE TREATMENT OPTION TO PATIENTS \n* TAKEDA PHARMACEUTICAL- PHASE 3 ALCANZA STUDY DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENT IN RATE OF OBJECTIVE RESPONSE LASTING ATLEAST 4 MONTHS \n* TAKEDA PHARMACEUTICAL CO LTD - EUROPEAN COMMISSION EXTENDED CURRENT CONDITIONAL MARKETING AUTHORIZATION OF ADCETRIS \n* TAKEDA PHARMACEUTICAL- EC APPROVED ADCETRIS FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA AFTER AT LEAST 1 PRIOR SYSTEMIC THERAPY Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T15:29:00.000+02:00",
    "crawled": "2018-01-22T16:02:36.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "commission",
        "approves",
        "adcetris",
        "cutaneous",
        "lymphoma",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "takeda",
        "pharmaceutical",
        "co",
        "ltd",
        "european",
        "commission",
        "approves",
        "brentuximab",
        "vedotin",
        "cutaneous",
        "lymphoma",
        "one",
        "prior",
        "systemic",
        "providing",
        "innovative",
        "treatment",
        "option",
        "patient",
        "takeda",
        "phase",
        "alcanza",
        "study",
        "demonstrated",
        "highly",
        "statistically",
        "significant",
        "improvement",
        "rate",
        "objective",
        "response",
        "lasting",
        "atleast",
        "month",
        "takeda",
        "pharmaceutical",
        "co",
        "ltd",
        "european",
        "commission",
        "extended",
        "current",
        "conditional",
        "marketing",
        "authorization",
        "adcetris",
        "takeda",
        "ec",
        "approved",
        "adcetris",
        "treatment",
        "adult",
        "patient",
        "cutaneous",
        "lymphoma",
        "least",
        "prior",
        "systemic",
        "therapy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}